CANF — Can Fite Biopharma Income Statement
0.000.00%
Last trade - 00:00- $14.60m
- $9.77m
- $0.67m
Annual income statement for Can Fite Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.763 | 0.853 | 0.81 | 0.743 | 0.674 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 14.9 | 13.7 | 10.9 | 8.94 | 8.8 |
| Operating Profit | -14.1 | -12.8 | -10.1 | -8.2 | -8.13 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -14.4 | -12.6 | -10.2 | -7.63 | -7.88 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -14.4 | -12.6 | -10.2 | -7.63 | -7.88 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -14.4 | -12.6 | -10.2 | -7.63 | -7.88 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -15.2 | -15.2 | -10.2 | -7.63 | -7.88 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.042 | -0.027 | -0.012 | -0.006 | -0.004 |
| Dividends per Share |